REGiMMUNE Entered into a License Agreement with San Fu Biotech to Develop and Commercialize RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease
Shots:
- REGiMMUNE will receive development milestones along with royalties on net profit, following the successful commercialization of RGI-2001 while SFB obtains the first rights of negotiation to develop and commercialize RGI-2001 for new indications in the authorized territories
- REGiMMUNE and SFB collaborated to advance the development of RGI-2001 in major Asian countries and will be responsible to conduct clinical trials to study the efficacy of RGI-2001 in aGvHD
- Both companies also plan to submit an IND application to TFDA to initiate clinical trials in Taiwan for the prophylaxis of aGvHD before the end of 2023. REGiMMUNE’s RGI-2001 is currently in P-III trial for the prophylaxis of aGVHD
Ref: regimmune | Image: regimmune
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
